SCHEMBL5541454

SCHEMBL5541454

[CH2]c1ccccc1NCc1cccc(OC(F)(F)C(F)(F)F)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 4/20 0.43
ABCG2 Q9UNQ0 2/20 0.43
KDM5A P29375 1/20 0.43
KDM4C Q9H3R0 1/20 0.43
KDM5B Q9UGL1 1/20 0.43
GRM2 Q14416 2/20 0.43
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
MAPK14 Q16539 1/20 0.39
FLT1 P17948 1/20 0.39
KDR P35968 1/20 0.39
P2RX7 Q99572 1/20 0.38
KCNN3 Q9UGI6 1/20 0.38
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
THRB P10828 1/20 0.36
PKM P14618 1/20 0.36
RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5543549 0.89 KDM5A (0.53) ABCB1ABCG2KDM5AKDM4CKDM5B
SCHEMBL5543900 0.85 FLT1 (0.39) MEN1KMT2AFLT1KDRP2RX7
SCHEMBL5537824 0.79 ABCB1 (0.66) ABCB1ABCG2GRM2MEN1KMT2A
SCHEMBL5534504 0.76 RXFP1 (0.56) MAPTRXFP1
SCHEMBL5545910 0.75 MAPT (0.42) KDM5AKDM4CKDM5BMEN1KMT2A
SCHEMBL5536813 0.74 APP (0.46) KDM5AKDM4CKDM5BMAPK14FLT1
SCHEMBL5543537 0.74 L3MBTL1 (0.44) MEN1KMT2AP2RX7KCNN3KDM4E
SCHEMBL2091050 0.74 CETP (0.39) MAPK14CARM1PRMT6
SCHEMBL5536417 0.73 KDM1A (0.46) MEN1KMT2AFLT1KDRP2RX7
SCHEMBL5540838 0.72 ADH1B (0.46) KDM5AKDM4CKDM5BGRM2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 ABCB1 2408/4885ABCG2 760/4885KDM5A 4851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.